European private equity firm, Cinven, today announces completion of its acquisition of Amdipharm, the family-owned international niche pharmaceuticals business, for a total consideration of £367 million. This follows Cinven’s acquisition of Mercury Pharma, an international specialty pharmaceuticals company, in August 2012.
Amdipharm will be merged, over time, with Cinven’s existing portfolio company, Mercury Pharma. The combined group has an enterprise value in excess of £830 million, with revenues approaching £250 million and a portfolio of more than 200 drugs.
Cinven originated these investments through its healthcare sector focus. Its strategy is to grow a global niche pharmaceuticals business, both organically and through further acquisition opportunities, including in emerging markets, and to build on the existing scale of the combined business.